Childhood brain tumors, residential insecticide exposure, and pesticide metabolism genes

Environmental Health Perspectives

Volumn 118, Issue 1, 2010, Pages 144-149

  Nielsen, Susan Searles ^a   McKean Cowdin, Roberta ^b   Farin, Federico M ^c   Holly, Elizabeth A ^d   Preston Martin, Susan ^b   Mueller, Beth A ^a,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acetylcholinesterase inhibition; Childhood cancer; Children; Gene environment interaction; Insecticides; Pesticides; Xenobiotic metabolism

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 3A1; ARYLDIALKYLPHOSPHATASE 1; CHOLINESTERASE; DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE 1; DIMETHYLANILINE MONOOXYGENASE 3; DNA; GLUTATHIONE TRANSFERASE T1; INSECTICIDE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BRAIN TUMOR; CHILD; CHILDHOOD BRAIN TUMOR; CONCEPTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; NEWBORN; NEWBORN SCREENING; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROMOTER REGION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ALDEHYDE DEHYDROGENASE; ARYLDIALKYLPHOSPHATASE; BRAIN NEOPLASMS; BUTYRYLCHOLINESTERASE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENVIRONMENTAL EXPOSURE; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; INFANT; INFANT, NEWBORN; INSECTICIDES; MALE; METABOLIC DETOXICATION, DRUG; OXYGENASES; PESTICIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT;

EID: 77149125895     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.0901226     Document Type: Article

References (44)

1. Babaoglu MO, Ocal T, Bayar B, Kayaalp SO, Bozkurt A. 2004. Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population. Eur J Clin Pharmacol 59:875.877.
2. Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, et al. 1992. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 50:1086.1103.
3. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. 2001. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428.1436.
4. Buck RJ, Ozkaynak H, Xue J, Zartarian VG, Hammerstrom K. 2001. Modeled estimates of chlorpyrifos exposure and dose for the Minnesota and Arizona NHEXAS populations. J Expo Anal Environ Epidemiol 11:253.268.
5. Buronfosse T, Moroni P, Benoît E, Rivière JL. 1995. Stereoselective sulfoxidation of the pesticide methiocarb by flavin-containing monooxygenase and cytochrome P450-dependent monooxygenases of rat liver microsomes. Anticholinesterase activity of the two sulfoxide enantiomers. J Biochem Toxicol 10:179.189.
6. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. 2003. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 111:1403.1409.
7. Clayton CA, Pellizzari ED, Whitmore RW, Quackenboss JJ, Adgate J, Sefton K. 2003. Distributions, associations, and partial aggregate exposure of pesticides and polynuclear aromatic hydrocarbons in the Minnesota Children's Pesticide Exposure Study (MNCPES). J Expo Anal Environ Epidemiol 13:100.111.
8. Cokuǧraş AN. 2003. Butyrylcholinesterase: structure and physiological importance. Turk J Biochem 28:54.61.
9. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, et al. 2003. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13:357.364.
10. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334.336.
11. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. 2005. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46:1239.1247.
12. Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. 2007. Epidemiology of brain tumors. Neurol Clin 25:867.890.
13. Furlong CE. 2007. Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. J Biochem Mol Toxicol 21:197.205.
14. Furnes B, Schlenk D. 2004. Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes. Toxicol Sci 78:196.203.
15. Furnes B, Schlenk D. 2005. Extrahepatic metabolism of carbamate and organophosphate thioether compounds by the flavin-containing monooxygenase and cytochrome P450 systems. Drug Metab Dispos 33:214.218.
16. Garcia-Closas M, Rothman N, Lubin J. 1999. Misclassification in case-control studies of gene-environment interactions: assessment of bias and sample size. Cancer Epidemiol Biomarkers Prev 8:1043.1050.
17. Hajjar NP, Hodgson E. 1980. Flavin adenine dinucleotide. dependent monooxygenase: its role in the sulfoxidation of pesticides in mammals. Science 209:1134.1136.
18. Hines RN, Luo Z, Hopp KA, Cabacungan ET, Koukouritaki SB, McCarver DG. 2003. Genetic variability at the human FMO1 locus: significance of a basal promoter yin yang 1 element polymorphism (FMO1*6). J Pharmacol Exp Ther 306:1210.1218.
19. Infante-Rivard C, Weichenthal S. 2007. Pesticides and childhood cancer: an update of Zahm and Ward's 1998 review. J Toxicol Environ Health B Crit Rev 10:81.99.
20. Kelada SN, Stapleton PL, Farin FM, Bammler TK, Eaton DL, Smith-Weller T, et al. 2003. Glutathione S-transferase M1, T1, and P1 polymorphisms and Parkinson's disease. Neurosci Lett 337:5.8.
21. Khoury MJ, Flanders WD. 1996. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! Am J Epidemiol 144:207.213.
22. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. 2002. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr Res 51:236.243.
23. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, Cashman JR. 2003. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab Dispos 31:854.860.
24. Leoni C, Buratti FM, Testai E. 2008. The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol Appl Pharmacol 233:343.352.
25. Levi PE, Hodgson E. 1988. Stereospecificity in the oxidation of phorate and phorate sulphoxide by purified FADcontaining mono-oxygenase and cytochrome P-450 isozymes. Xenobiotica 18:29.39.
26. Leviev I, Deakin S, James RW. 2001. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 42:528.535.
27. Leviev I, James RW. 2000. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516.521.
28. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, et al. 2000. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 10:767.779.
29. Maetzler W, Keller S, Michelis J, Koehler N, Stransky E, Becker C, et al. 2009. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis 35:296.301.
30. Morimoto LM, White E, Newcomb PA. 2003. Selection bias in the assessment of gene-environment interaction in casecontrol studies. Am J Epidemiol 158:259.263.
31. Mutch E, Daly AK, Williams FM. 2007. The relationship between PON1 phenotype and PON1-192 genotype in detoxification of three oxons by human liver. Drug Metab Dispos 35:315.320.
32. Paynter RA, Skibola DR, Skibola CF, Buffler PA, Wiemels JL, Smith MT. 2006. Accuracy of multiplexed Illumina platform-based single-nucleotide polymorphism genotyping compared between genomic and whole genome amplified DNA collected from multiple sources. Cancer Epidemiol Biomarkers Prev 15:2533.2536.
33. Phillips IR, Shephard EA. 2008. Flavin-containing monooxygenases: mutations, disease and drug response. Trends Pharmacol Sci 29:294.301.
34. Pogoda JM, Preston-Martin S. 1997. Household pesticides and risk of pediatric brain tumors. Environ Health Perspect 105:1214.1220.
35. Preston-Martin S, Pogoda JM, Mueller BA, Holly EA, Lijinsky W, Davis RL. 1996. Maternal consumption of cured meats and vitamins in relation to pediatric brain tumors. Cancer Epidemiol Biomarkers Prev 5:599.605.
36. Satomichi A, Nakajima Y, Takeuchi A, Takagaki Y, Saigenji K, Shibuya A. 2000. Primary structure of human hepatocellular carcinoma-associated aldehyde dehydrogenase. Biochim Biophys Acta 1481:328.336.
37. Searles Nielsen S, Mueller BA, De Roos AJ, Checkoway H. 2008. Newborn screening archives as a specimen source for epidemiologic studies: feasibility and potential for bias. Ann Epidemiol 18:58.64.
38. Searles Nielsen S, Mueller BA, De Roos AJ, Viernes HM, Farin FM, Checkoway H. 2005. Risk of brain tumors in children and susceptibility to organophosphorus insecticides: the potential role of paraoxonase (PON1). Environ Health Perspect 113:909.913.
39. Slotkin TA, Seidler FJ, Fumagalli F. 2008. Targeting of neurotrophic factors, their receptors, and signaling pathways in the developmental neurotoxicity of organophosphates in vivo and in vitro. Brain Res Bull 76:424.438.
40. Stephens M, Donnelly P. 2003. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162.1169.
41. Usmani KA, Karoly ED, Hodgson E, Rose RL. 2004. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily. Drug Metab Dispos 32:333.339.
42. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. 2004. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434.442.
43. World Health Organization. 1976. International Classification of Diseases for Oncology. 1st ed. Geneva:World Health Organization.
44. Zhang J, Cashman JR. 2006. Quantitative analysis of FMO gene mRNA levels in human tissues. Drug Metab Dispos 34:19.26.